DNA Repair Capacity of Afamelanotide on Ultraviolet Radiation-induced DNA Damage in Healthy Volunteers
Launched by CLINUVEL (UK) LTD. · May 6, 2022
Trial Information
Current as of April 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy male or female volunteers (aged 18-45) with Fitzpatrick skin types I, II or III.
- • Written informed consent obtained from volunteers prior to study-start.
- Exclusion Criteria:
- • Female who is pregnant or lactating.
- • Females of child-bearing potential not using adequate contraceptive measures or a lifestyle excluding pregnancy.
- • Sexually active man with a partner of child-bearing potential who is not using adequate contraceptive measures.
- • Any significant illness during the four weeks before the study screening period.
- • Taking known photosensitisers.
About Clinuvel (Uk) Ltd.
Clinuvel (UK) Ltd. is a specialized biopharmaceutical company focused on developing innovative therapies for patients with rare skin disorders and conditions related to photoprotection. As a subsidiary of Clinuvel Pharmaceuticals Limited, the company leverages cutting-edge research and technology to advance its pipeline of treatments aimed at enhancing patient quality of life. With a commitment to scientific excellence and patient-centered outcomes, Clinuvel (UK) Ltd. collaborates with healthcare professionals and regulatory bodies to bring safe and effective solutions to market, addressing unmet medical needs in the dermatology field.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Clinuvel Investigational Site, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials